{"id":"NCT04949841","sponsor":"LEO Pharma","briefTitle":"Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials","officialTitle":"A Phase 3 Extension Trial of DELTA 1 and DELTA 2 to Evaluate the Long-term Safety of a Twice-daily Treatment With Delgocitinib Cream 20 mg/g as Needed for up to 36 Weeks in Adult Subjects With Chronic Hand Eczema (DELTA 3)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-08-23","primaryCompletion":"2023-09-18","completion":"2023-09-18","firstPosted":"2021-07-02","resultsPosted":"2025-01-20","lastUpdate":"2025-04-08"},"enrollment":801,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hand Eczema"],"interventions":[{"type":"DRUG","name":"Delgocitinib","otherNames":[]}],"arms":[{"label":"As-needed treatment with delgocitinib","type":"EXPERIMENTAL"}],"summary":"The purpose of this extension trial is to evaluate the long-term safety of delgocitinib.\n\nSubjects will visit the clinic every 4 week to assess the safety and efficacy of the treatment, until Week 36. A final follow-up phone call is planned on Week 38.","primaryOutcome":{"measure":"Number of Treatment-emergent Adverse Events From Baseline up to Week 38","timeFrame":"From baseline up to Week 38","effectByArm":[{"arm":"As-needed Treatment With Delgocitinib","deltaMin":1238,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":95,"countries":["Belgium","Canada","Denmark","France","Germany","Italy","Netherlands","Poland","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":801},"commonTop":["COVID-19","Nasopharyngitis","Upper respiratory tract infection","Hand dermatitis","Influenza"]}}